Skip to main content
. 2022 Mar 28;20:96. doi: 10.1186/s12957-022-02566-6

Table 4.

The relationship between the expression of STEAP2 and clinicopathological features of NSCLC patients

Pathological features N STEAP2 χ2 P
High expression Low expression
n (%) n (%)
Age 0.198 0.656
 ≤60 130 23 (17.7) 107 (82.3)
 >60 128 20 (15.6) 108 (84.4)
Sex 0.030 0.864
 Male 159 27 (17.0) 132 (83.0)
 Female 99 16 (16.2) 83 (83.8)
TNM clinical stages 19.379 0.000
 I and II stages 108 31 (28.7) 77 (71.3)
 III and IV stages 150 12 (8.0) 138 (92.0)
Histological type 0.230※ 0.891※
 Squamous carcinoma 121 20 (16.5) 101 (83.5) 9.408# 0.009#
  I grade 32 13 (40.6) 19 (59.4)
  II grade 48 13 (27.1) 35 (72.9)
  III grade 41 4 (9.8) 37 (90.2)
 Adenocarcinoma 112 18 (16.1) 94 (83.9) 14.298* 0.006*
  Lepidic-predominant 25 12 (48.0) 13 (52.0)
  Acinar-predominant 21 9 (42.9) 12 (57.1)
  Papillary-predominant 19 6 (31.6) 13 (68.4)
  Solid-predominant 24 3 (12.5) 21 (87.5)
  Micropapillary-predominant 23 2 (8.7) 21(91.3)
 Adenosquamous carcinoma 25 5 (20.0) 20 (80.0)
Lymphatic metastasis 35.352 0.000
 N0 95 33 (34.7) 62 (65.3)
 N+ 163 10 (6.1) 153 (93.9)

※There was no statistical significance in the high expression rate of STEAP2 in different pathological types of NSCLC, such as squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma (P > 0.05). #There was statistical significance in the high expression rate of STEAP2 in different histological grades of squamous cell carcinoma, when the histological grade increased, the high expression rate of STEAP2 decreased (P < 0.05). *There was statistical significance in the high expression rate of STEAP2 in different pathological subtypes of adenocarcinoma; the high expression rate of STEAP2 in well-differentiated lepidic adenocarcinoma was significantly higher than that in poorly differentiated solid and micropapillary adenocarcinoma (P < 0.05)

HHS Vulnerability Disclosure